Evidence map›Paper›PMID 29914187›Full record

ReviewJournal of clinical medicine2018

Prostate-Associated Gene 4 (PAGE4): Leveraging the Conformational Dynamics of a Dancing Protein Cloud as a Therapeutic Target.

Ravi Salgia, Mohit Kumar Jolly, Tanya Dorff, Clayton Lau, Keith Weninger, John Orban, Prakash Kulkarni

Open access · goldAbstract readReview
In one paragraph

Review in Journal of clinical medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Placenta: an old organ with new functions.Frontiers in immunology · 2024
    Review
  2. Review
  3. Review
  4. Review
  5. Presence and structure-activity relationship of intrinsically disordered regions across mucins.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2020
    Article
  6. Review
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Ravi SalgiaDepartment of Medical Oncology and Therapeutics Research, City of Hope, Duarte, CA 91010, USA. rsalgia@coh.org.
Mohit Kumar JollyCenter for Theoretical Biological Physics, Rice University, Houston, TX 77005, USA. mkjolly.15@gmail.com.ORCID 0000-0002-6631-2109
Tanya DorffDepartment of Medical Oncology and Therapeutics Research, City of Hope, Duarte, CA 91010, USA. tdorff@coh.org.
Clayton LauDivision of Urology and Urologic Oncology, City of Hope, Duarte, CA 91010, USA. Cllau@coh.org.
Keith WeningerDepartment of Physics, North Carolina State University, Raleigh, NC 27695, USA. krwening@ncsu.edu.
John OrbanInstitute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD 20850, USA. orban@ibbr.umd.edu.
Prakash KulkarniDepartment of Medical Oncology and Therapeutics Research, City of Hope, Duarte, CA 91010, USA. pkulkarni@coh.org.
City of Hope · USCenter for Theoretical Biological Physics · USNorth Carolina State University · USUniversity of Maryland, Baltimore · US

Funding

PAGE4 as a Novel Target for Prostate Cancer PreventionR21CA181730 · NCI · UNIV OF MARYLAND, COLLEGE PARK · PI KULKARNI, PRAKASH, ORBAN, JOHN · 2014 to 2015
$364k
NCI NIH HHS R21 CA181730
6 · The paper itself

Abstract

Prostate cancer (PCa) is a leading cause of mortality and morbidity globally. While genomic alterations have been identified in PCa, in contrast to some other cancers, use of such information to personalize treatment is still in its infancy. Here, we discuss how PAGE4, a protein which appears to act both as an oncogenic factor as well as a metastasis suppressor, is a novel therapeutic target for PCa. Inhibiting PAGE4 may be a viable strategy for low-risk PCa where it is highly upregulated. Conversely, PAGE4 expression is downregulated in metastatic PCa and, therefore, reinstituting its sustained expression may be a promising option to subvert or attenuate androgen-resistant PCa. Thus, fine-tuning the levels of PAGE4 may represent a novel approach for personalized medicine in PCa.

Indexed as

ADTCancer/Testis AntigenIADPAGE4prostate cancersymptomatic BPH

Identifiers

PMID29914187
PMCPMC6025510
OpenAlexW2808537379

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.